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Abstract
 .The antisecretory factor AF is a new regulatory protein, produced in the human pituitary gland, which reverses
intestinal fluid secretion induced by cholera toxin. We have previously described the cDNA-cloning and characterization of
the expressed gene. The aim of this study was to identify the region responsible for the antisecretory activity in the
AF-molecule. The recombinant full-length AF has an increased ability to inhibit hypersecretion after treatment with trypsin,
indicating that the activity of AF is achieved by smaller peptide fragments. To localize the active region of AF, we
expressed truncated forms of the recombinant protein and examined their antisecretory activity against cholera toxin-in-
duced fluid secretion in rat. Nine recombinant AF peptides and four smaller peptides made by solid phase synthesis were
tested. Five of the peptides lacked all activity, whereas seven of them were highly active, a dose between 4 and 15 pmol
causing a half-maximal inhibition. All the active peptides contained amino acid 36–42 of the AF sequence, whereas none of
the inactive peptides contained this sequence. Our results suggest that the site of the antisecretory activity resides in a small
 .region I VCHSKTR between position 35 and 42 of the AF molecule. q 1997 Elsevier Science B.V.
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1. Introduction
The permeability of the intestinal epithelium to
water and electrolytes is regulated by peptides, which
are expressed both in the gut and in the central
w xnervous system 1,2 . Some of them including va-
 .soactive intestinal peptide VIP , substance P, se-
cretin, pituitary adenylate cyclase activating polypep-
tide, natriuretic peptide and endothelin increase the
Abbreviations: AF, antisecretory factor; PCR, polymerase
chain reaction; VIP, vasoactive intestinal peptide; GST, glu-
tathione S-transferase
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transport from the serosal to the mucosal side of the
w xintestinal epithelium 2,3 . Bacterial enterotoxins seem
to mimic the effect of neuropeptides on the enteric
nervous system, an action causing fluid secretion and
diarrhea. Thus, cholera toxin from Vibrio cholerae
w xmimic the action of VIP 4 , whereas toxin A from
Clostridium difficile mimics the action of substance P
w x5 . Furthermore, both VIP and substance P might be
involved in the action of each enterotoxin on the
w xenteric nervous system 4,5 .
Other peptides, such as neuropeptide Y, peptide
YY, somatostatin, enkephalines and sorbin, are known
to increase the absorption of electrolytes and fluid in
w xthe gut 2,6 . Of these, somatostatin, peptide YY and
enkephalins have been shown to inhibit cholera
0925-4439r97r$19.00 q 1997 Elsevier Science B.V. All rights reserved.
 .PII S0925-4439 97 00066-5
( )E. Johansson et al.rBiochimica et Biophysica Acta 1362 1997 177–182178
w xtoxin-induced fluid secretion 7–9 . Recently, we iso-
lated and sequenced cDNA expressing a new 41 kDa
 .protein called antisecretory factor AF , which in-
hibits cholera toxin-induced fluid secretion in the
w x y12small intestine 10 ; 10 mol of AF causes a half-
maximal inhibition in rats and 10y11 mol in pigs
w xexposed to cholera toxin 11 . The AF protein is
found in the pituitary gland, central nervous system
and intestinal mucosa and is secreted into the blood
after challenge with bacterial enterotoxins. AF is a
potent antagonist of chloride ion transport across
nerve cell membranes and probably influences the
intestinal permeability via the enteric nervous system
w x12 .
The aim of the present study is to determine the
active site of the AF molecule by which it inhibits
intestinal hypersecretion. The capacity of truncated
forms of AF to inhibit cholera toxin-induced fluid
secretion in intestinal loops in rat is tested.
2. Material and methods
2.1. cDNA cloning of AF-fragments
Sense and antisense oligonucleotides correspond-
ing to the human AF-sequence were used in PCR
amplification of a set of overlapping products with
w xthe previously isolated AF-1 cDNA clone 10 . The
fragments were obtained by using primer pairs ArB,
 .ArC, FrC, DrE, FrE, DrG and HrI Table 1 ,
which have EcoR1 sites in frame with the pGEX-1lT
 .expression vector Pharmacia, Sweden . The seven
resulting PCR-products were digested with EcoR1,
 .purified with Sephaglas BandPrep Kits Pharmacia ,
ligated to the EcoR1-site of pGEX-1lT and trans-
fected into Epicurian Coli XL1-Blue cells Strata-
. w xgene as previously described 10 . The inserted DNAs
were verified by the dideoxy chain termination se-
w x quencing 13 with Sequenase version 2.0 US Bio-
.chemical using the pGEX forward and reverse uni-
 .versal primers Pharmacia .
2.2. Expression and purification of fusion proteins
 .Glutathione S-transferase GST fusion proteins
were expressed in Escherichia coli after induction
with 0.1 mM isopropyl-b-D-thiogalactopyranoside
w x14 . Cells were harvested 4 h after induction. After
sonication and centrifugation, the supernatant con-
taining the expressed fusion proteins was purified by
passing the lysates through glutathione–agarose
 .Pharmacia . The recombinant AF proteins were re-
 .leased from GST 26-kDa by bovine thrombin treat-
 .ment 10 units for 2 h at 228C and the pure AF
peptides were collected and their concentration deter-
w xmined 10 .
2.3. Trypsin-digestion
 .Purified fusion protein AF-1 100 ng was incu-
bated with 10 ng trypsin type XI: from bovine pan-
Table 1
Sequences of the oligonucleotide PCR Primers
Primer Sequence Position
X XA 5 -CGCGAATTCATGGTGTTGGAAAGCAC-3 1–16
X XB 5 -GACGAATTCTGATTCTTGCCTTGTCGG-3 315–297
X XC 5 -GCGAATTCGGGTTGGACAGTATGTAGCTTG-3 240–218
X XD 5 -GGCGAATTCTTACCCACCAGGCTG-3 61–78
X XE 5 -GAGAATTCAAGGCCCACGTTGTTCTCAGGG-3 153–132
X XF 5 -AGCGAATTCGTTTGTCATTCAAAGACCCGCAG-3 106–128
X XG 5 -CGGAATTCAACTATGTTGACAGCATCCTGC-3 108–87
X XH 5 -CGGAATTCCGCAGCAACCCTGAGAA-3 124–140
X XI 5 -CGGAATTCAGTGTCTGGGGTGAGTGTGGT-3 207–184
These oligonucleotide primers were used for PCR amplification of AF cDNA. The position refers to the sequence within the open reading
w x .frame of AF cDNA 10 and Fig. 1 .
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Table 2
Biological effects of peptides made by recombinant DNA-tech-
nique or solid phase synthesis
Code Oligonucleotide Peptide Inhibition of
cholera secretion
 .pmol
AF-1 1–1131 1–376 1–10
AF-2 186–1131 63–376 )100
AF-3 361–1131 121–376 )100
AF-4 1–315 1–105 6
AF-5 1–240 1–80 4
AF-6 106–240 36–80 6
AF-7 61–153 21–51 5
AF-8 61–108 21–36 )100
AF-9 124–207 42–69 )100
 .AF-10 106–153 36–51 5
AF-11 y 35–46 14
AF-12 y 35–42 15
AF-13 y 36–41 )100
The peptides AF-1 to AF-9 were produced in E. coli transfected
 .with constructs made from AF-cDNA fragments see Fig. 1 and
pGEX-1lT plasmid. For each oligonucleotide fragment, the start
and end is related to the corresponding basepairs in the open
 .reading frame of AF sAF-1 . The positions of amino acid-re-
sidues in AF at the start and end of each peptide is also given.
The four smallest peptides AF-10 to AF-13 were produced by
solid phase organic synthesis. The purified AF-peptides were
tested in rat for inhibition of cholera secretion as described in
 .Fig. 2; the amount pmol causing halfmaximal inhibition is
noted for each peptide.
.creas, Sigma for 1 h at 228C before the biological
activity was tested in the rat loop assay. A similar
sample but without AF-1 was prepared as a control in
the animal test. The trypsin was not inactivated due
to a possible risk of thermolability of the AF protein.
2.4. Sequence analysis
The nucleotide sequence and the deduced protein
sequence were analyzed with the MacVector DNA
 .and protein analysis program Eastman . Hydropathy
measurements were determined by using the algo-
w xrithm of Kyte and Doolittle 15 .
2.5. Organic chemical synthesis
The shortest tested recombinant AF peptide show-
ing bioactivity, AF-10 and three shorter peptides
 .AF-11, AF-12 and AF-13 Table 2 were synthesized
by organic chemical synthesis on solid phase using a
430A peptide synthesizer Applied Biosystems, Fos-
.ter City, CA . The peptides were purified to )95%
purity on reversed phase HPLC, using a Delta Pak
 .C18 300A column Waters, Milford, MA with a
mobile phase of waterracetonitrile containing 0.1%
 .trifluoric acid linear gradient .
2.6. Antisecretory acti˝ity
The antisecretory activity was measured in a previ-
w xously described rat intestinal loop model 16 . In
brief, a jejunal loop was challenged with 3 mg of
cholera toxin. Various amounts of AF peptides dis-
 .solved in 2 ml of PBS or buffer alone control were
injected intravenously 20–30 s before challenge with
cholera toxin. The weight of the accumulated fluid in
 .the intestinal loop mgrcm was recorded after 5 h.
All samples were tested blindly in the dose range
1–10 pmol; peptides with no activity in this range
were further tested in a 10-fold higher dose. Each
preparation was tested in at least six rats, except for
the trypsin-digested AF-1 and its trypsin control,
Fig. 1. Horizontal map of AF cDNA as template. The figure shows the expressed part of ten different cDNA fragments generated by
PCR. The primers used for PCR are given in Table 1. The number of base pairs are marked.
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which were tested in four plus four animals. Fisher’s
protected least significant difference was used for
statistical analysis of the data.
3. Results
3.1. Construction and expression of AF cDNA
Ten different AF-cDNA constructs were used Fig.
.1 , of which three AF-1, AF-2 and AF-3 have been
w xdescribed in a previous publication 10 . The addi-
 .tionally seven AF-cDNA fragments AF-4 to AF-10
were generated by PCR with AF-1 as template Fig.
.1, Table 2 . The expression constructs were ligated
into the EcoR1-site of the pGEX-1lT-vector so that
the ORF was in frame with the GST protein. The
constructs were transformed into E. coli, and overex-
pression of the fusion proteins was induced with
isopropyl-b-D-thiogalactopyranoside, giving moder-
ate levels of recombinant proteins. The fusion pro-
teins were purified on glutathione–agarose, and the
AF peptides were cleaved from the bound GST with
thrombin.
3.2. Trypsin treatment
The biological activity of the whole AF-1 protein
produced in E. coli was tested in a rat loop model.
When the protein was enzyme-digested with trypsin,
the capacity to inhibit cholera toxin-induced secretion
was enhanced two-fold compared with the untreated
  ..AF-1 Fig. 2 a . No change in activity was registered
after injection of a trypsin control sample. The in-
creased antisecretory capacity of AF after incubation
with trypsin indicated that the activity was exerted by
a peptide fragment of the AF molecule.
3.3. Testing of recombinant AF peptides
Nine truncated AF recombinant peptides were
tested in the rat model. First, two peptides containing
the C-terminal part of the AF molecule, AF-2 and
 .AF-3 were tested Table 2 . Not one of them had
activity when tested in the dose interval 1–100 pmol,
i.e. 1–100 times the dose of AF giving half-maximal
inhibition. In contrast, AF-4 containing the N-termi-
 .nal part of the AF molecule residues 1–105 , caused
a dose-dependent inhibition of cholera secretion Fig.
 ..2 b . One pmol of AF-4 reduced the response by
 .Fig. 2. Biological activity of recombinant AF-1 3 nmol before
 .  .and after trypsin-incubation a and of AF-4 b . Recombinant
peptides or buffer controls were injected intravenously in rat;
3mg of cholera toxin was injected into an intestinal loop; after
 .5 h, the accumulated fluid mgrcm intestine was measured.
Each value represents the mean"S.E. of a group of four to six
animals.
 .37% p-0.01, ns6 , whereas 5 and 25 pmol re-
duced it by 48 and 76%, respectively. The N-terminal
AF-4 peptide was further truncated into smaller pep-
tides: AF-5, AF-6, AF-7, AF-8, AF-9 and AF-10
 .Table 2 . AF-5, containing residue 1–80 and AF-6,
containing residue 36–80, were both active in doses
 .between 1–10 pmol. Similar doses of AF-7 21–51
 .and AF-10 36–51 also exerted activity, whereas
 .  .AF-8 21–36 and AF-9 42–69 had no activity.
Thus, the activity of AF-1 seems to reside in the
16-meric peptide AF-10, having the sequence VCH-
SKTRSNPENNVGL.
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 .  .Fig. 3. Biological activity of AF-10 a and AF-12 b peptides
produced by solid phase synthesis. The experimental details are
given in Fig. 2. Each value represents the mean"S.E. of a group
of six animals.
3.4. Testing of peptides made by solid phase synthesis
The activity of the AF-10 peptide was confirmed
by testing a peptide made by means of solid phase
synthesis. The biological activity of the produced
AF-10 peptide was similar to that made by the re-
combinant technique, the dose exerting a half-maxi-
  ..mal inhibition being about 5 pmol Fig. 3 a .
AF-10 was further truncated into three small pep-
tides AF-11, AF-12 and AF-13 which were produced
 .by solid phase technique Table 2 . These peptides
are all relatively hydrophilic and have isoelectric
 .points between 8 and 10. AF-11 IVCHSKTRSNPE
 .and AF-12 IVCHSKTR were both potent inhibitors
of cholera secretion, however, less potent than AF-10
 .Fig. 3 . In contrast, the hexapeptide AF-13
 .VCHSKT had no activity when tested in the inter-
val 1–100 pmol.
4. Discussion
The results suggest that the antisecretory activity
of human AF resides in a short sequence between
amino acids 35 and 42 having the sequence
 .I VCHSKTR. The peptides containing this sequence
 .with or without a N-terminal isoleucine were active,
whereas the AF peptides outside this sequence were
inert. In most peptides known to inhibit intestinal
secretion, the activity seems to reside in short se-
quences: in sorbin the active site is a heptapeptide
w x w x17 ; in peptide YY a 15-peptide 18 ; in somatostatin
w xan octapeptide 19 ; and in opiates a pentapeptide
w x20 . The activity of AF was increased after treatment
with trypsin, suggesting that AF also in vivo might be
activated by hydrolyses. Such a conversion into an
active peptide occurs in like manner with the precur-
sor proteins to opiates and somatostatin.
Like AF, somatostatin and enkephalin have been
w xused to reverse cholera toxin-induced secretion 7,9 .
Whereas somatostatin is active at nanomole and
enkephalin at micromole concentrations, AF and its
peptide derivatives are active at picomole levels.
There is, however, no homology between AF or its
active peptide with any other of the antisecretory
peptides and, accordingly, their receptors should also
differ. Like other peptide receptors mediating antise-
cretory activity, the AF receptor appears to reside in
w xthe enteric nerve system 2 . The active N-terminal
part of the AF molecule contains four cysteine groups,
whereas no cysteine is present in the remaining two-
thirds of the molecule. Intrachain and interchain
disulfide cross linkage are likely to occur in the
secreted form of the AF peptide. The free sulfide
group of the active heptapeptide might be essential
for the activity and its susceptibility to oxidation
should be tested.
A second activity of the AF molecule is its anti-in-
flammatory quality observed in the rat’s intestine
w xafter exposure to toxin A from C. difficile 21 . Toxin
A binds to receptors resembling the glycolipid B5 or
w xX2 22 , whereas cholera toxin binds to receptors
w xresembling GM1–ganglioside 23 . After binding, the
two toxins are internalized into the cells where they
exert enzymatic activities: cholera toxin catalyzing
w xADP-ribosylation of adenylate cyclase 24 and toxin
A transferring glucose residues to the rho protein
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w x25 . The permeability changes of the two toxins are
mediated by the enteric nervous system through which
w xsystem AF seems also to exert its effects 11,12 . To
determine whether the same receptor is involved in
the antagonistic action of AF on both types of toxic-
ity, it is crucial to investigate the activity of the
various truncated AF peptides on toxin A-mediated
inflammation and fluid secretion.
The cellular receptor for AF and the possible
intracellular signal transduction triggered by the re-
ceptor–agonist interaction are unknown. However,
the C-terminal part of AF has been shown to bind to
polyubiquitin and was therefore suggested to be a
regulatory protein in the polyubiquitin–proteasome
w xcomplex 26 . The transfection of a polyubiquitin
gene into the intestinal mucosa of calves is known to
w xbe the cause of the lethal bovine virus diarrhea 27 .
Because ubiquitin is a stress protein known to be
induced during neurological and inflammatory bowel
w xdiseases 28,29 , it might mediate the action of en-
terotoxins on the enteric nerve system that lead to
intestinal secretion and diarrhea.
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